A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

Nektar Therapeutics shares jumped 35.3% in extended trading Monday after the company said it would release topline results ...

Skin is more than a reflection in the mirror it’s the largest organ of your body, toiling away to shield you from the outside ...

Shares of Nektar Therapeutics soared after the company said it would release topline data from a study of its atopic dermatitis treatment rezpegaldesleukin. The stock was up 31% at $12.49 in Monday's ...

Investing.com -- Nektar Therapeutics (NASDAQ: NKTR) stock surged 20% following the company’s announcement that it will present top-line data from its REZOLVE-AD Phase 2b clinical trial for atopic ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

Nektar Therapeutics said it would release topline data from a study of its atopic dermatitis treatment rezpegaldesleukin on Tuesday. Shares climbed 27% to $12.15 in after-hours trading Monday.

Incyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the ...

An itchy scalp may be related to your hair-washing schedule, but may stem from various other causes, including skin ...

Discover a study that found that children with early AD were more likely to develop food allergies, whereas those with later ...

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...